Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.

Three types of vaccine, all expressing the same antigen from Plasmodium berghei, or a CD8+ T cell epitope from that antigen, were compared for their ability to induce CD8+ T cell responses in mice. Higher levels of lysis and numbers of IFN-gamma secreting T cells were primed with Ty virus-like parti...

Full description

Bibliographic Details
Main Authors:	Gilbert, S, Schneider, J, Plebanski, M, Hannan, C, Blanchard, T, Smith, G, Hill, A
Format:	Journal article
Language:	English
Published:	1999

Similar Items

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
by: Moorthy, V, et al.
Published: (2003)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
by: Schneider, J, et al.
Published: (1998)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
by: Moorthy, V, et al.
Published: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
by: Moorthy, V, et al.
Published: (2003)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
by: Hanke, T, et al.
Published: (1998)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003)

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
by: Dégano, P, et al.
Published: (1999)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
by: López-Camacho, C, et al.
Published: (2019)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
by: Alharbi, N, et al.
Published: (2015)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
by: Behboudi, S, et al.
Published: (2004)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

The production of hybrid Ty:IFN virus-like particles in yeast.
by: Malim, M, et al.
Published: (1987)

An immunological analysis of Ty1 virus-like particle structure.
by: Brookman, J, et al.
Published: (1995)

The expression of hybrid HIV:Ty virus-like particles in yeast.
by: Adams, SE, et al.
Published: (1987)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
by: Schneider, J, et al.
Published: (2001)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
by: Hanke, T, et al.
Published: (1999)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
by: Goonetilleke, N, et al.
Published: (2003)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
by: Winslow, R, et al.
Published: (2017)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
by: Hanke, T, et al.
Published: (2007)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
by: Hanke, T, et al.
Published: (2002)

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
by: Boyd, A, et al.
Published: (2013)

Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
by: Boyd, A, et al.
Published: (2013)

Virus-like particles as vaccine adjuvants.
by: Gilbert, S
Published: (2001)

Virus-like particle vaccines
by: Mukhopadhyay, E, et al.
Published: (2022)

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
by: Webster, D, et al.
Published: (2006)

Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast.
by: Mellor, J, et al.
Published: (1985)

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs
by: Busquets, N, et al.
Published: (2011)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves.
by: Bull, T, et al.
Published: (2014)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
by: Webster, D, et al.
Published: (2005)

A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).
by: Gilmour, J, et al.
Published: (1989)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
by: Mwau, M, et al.
Published: (2004)